Radiomic analysis to predict local response in locally advanced pancreatic cancer treated with stereotactic body radiation therapy

被引:28
|
作者
Gregucci, Fabiana [1 ]
Fiorentino, Alba [1 ]
Mazzola, Rosario [2 ]
Ricchetti, Francesco [2 ]
Bonaparte, Ilaria [1 ]
Surgo, Alessia [1 ]
Figlia, Vanessa [2 ]
Carbonara, Roberta [1 ]
Caliandro, Morena [1 ]
Ciliberti, Maria Paola [1 ]
Ruggieri, Ruggero [2 ]
Alongi, Filippo [2 ,3 ]
机构
[1] Gen Reg Hosp F Miulli, Radiat Oncol Dept, Str Prov 127, I-70021 Acquaviva Delle Fonti Ba, Italy
[2] IRCCS Sacro Cuore Don Calabria Hosp, Adv Radiat Oncol Dept, Negrar Verona, Italy
[3] Univ Brescia, Brescia, Italy
来源
RADIOLOGIA MEDICA | 2022年 / 127卷 / 01期
关键词
Radiomics; Pancreatic cancer; Stereotactic body radiation therapy; Local control; Predictive analysis; STROMAL BIOLOGY; HETEROGENEITY; GEMCITABINE; RADIOTHERAPY; IMAGES;
D O I
10.1007/s11547-021-01422-z
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Aim of this study is to assess the ability of contrast-enhanced CT image-based radiomic analysis to predict local response (LR) in a retrospective cohort of patients affected by pancreatic cancer and treated with stereotactic body radiation therapy (SBRT). Secondary aim is to evaluate progression free survival (PFS) and overall survival (OS) at long-term follow-up. Methods Contrast-enhanced-CT images of 37 patients who underwent SBRT were analyzed. Two clinical variables (BED, CTV volume), 27 radiomic features were included. LR was used as the outcome variable to build the predictive model. The Kaplan-Meier method was used to evaluate PFS and OS. Results Three variables were statistically correlated with the LR in the univariate analysis: Intensity Histogram (StdValue feature), Gray Level Cooccurrence Matrix (GLCM25_Correlation feature) and Neighbor Intensity Difference (NID25_Busyness feature). Multivariate model showed GLCM25_Correlation (P = 0.007) and NID25_Busyness (P = 0.03) as 2 independent predictive variables for LR. The odds ratio values of GLCM25_Correlation and NID25_Busyness were 0.07 (95%CI 0.01-0.49) and 8.10 (95%CI 1.20-54.40), respectively. The area under the curve for the multivariate logistic regressive model was 0.851 (95%CI 0.724-0.978). At a median follow-up of 30 months, median PFS was 7 months (95%CI 6-NA); median OS was 11 months (95%CI 10-22 months). Conclusions This analysis identified a radiomic signature that correlates with LR. To confirm these results, prospective studies could identify patient sub-groups with different rates of radiation dose-response to define a more personalized SBRT approach.
引用
下载
收藏
页码:100 / 107
页数:8
相关论文
共 50 条
  • [41] STEREOTACTIC BODY RADIOTHERAPY AND GEMCITABINE FOR LOCALLY ADVANCED PANCREATIC CANCER
    Mahadevan, Anand
    Jain, Sanjay
    Goldstein, Michael
    Miksad, Rebecca
    Pleskow, Douglas
    Sawhney, Mandeep
    Brennan, Darren
    Callery, Mark
    Vollmer, Charles
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : 735 - 742
  • [42] Chemoradiotherapy Versus Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer (CRiSP): An International Systematic Review and Meta-Analysis
    Tchelebi, L.
    Lehrer, E. J.
    Trifiletti, D. M.
    Zaorsky, N. G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E247 - E247
  • [43] Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer
    Wu, Guangyin
    Baine, Michael J.
    Zhao, Nan
    Li, Sicong
    Li, Xiaobo
    Lin, Chi
    BMC CANCER, 2019, 19 (01)
  • [44] Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy Compared to Conventional Fractionated Radiation Therapy in Patients With Locally Advanced Pancreatic Cancer
    Wu, G.
    Zhao, N.
    Li, S.
    Baine, M.
    Lin, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E199 - E199
  • [45] Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer
    Guangyin Wu
    Michael J. Baine
    Nan Zhao
    Sicong Li
    Xiaobo Li
    Chi Lin
    BMC Cancer, 19
  • [46] Adaptive MRI-guided stereotactic body radiation therapy for locally advanced pancreatic cancer - A phase II study
    Ejlsmark, Mathilde Weisz
    Bahij, Rana
    Schytte, Tine
    Hansen, Christian Ronn
    Bertelsen, Anders
    Mahmood, Faisal
    Mortensen, Michael Bau
    Detlefsen, Sonke
    Weber, Britta
    Bernchou, Uffe
    Pfeiffer, Per
    RADIOTHERAPY AND ONCOLOGY, 2024, 197
  • [47] Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review Using 2 Cell Survival Models
    Desai, S. C.
    Garg, M. K.
    Guha, C.
    Ohri, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E219 - E219
  • [48] Pathologic Outcomes in Borderline Resectable and Locally Advanced Pancreatic Cancer Patients Receiving Neoadjuvant Stereotactic Body Radiation Therapy
    Rosati, L. M.
    He, J.
    Moningi, S.
    Hacker-Prietz, A.
    Huebner, T. A.
    Assadi, R. K.
    Laheru, D. A.
    Zheng, L.
    De Jesus-Acosta, A.
    Le, D. T.
    Fishman, E. K.
    Hruban, R. H.
    Hirose, K.
    Makary, M. A.
    Cameron, J. L.
    Pawlik, T. M.
    Wolfgang, C. L.
    Weiss, M. J.
    Ellsworth, S. G.
    Herman, J. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E127 - E128
  • [49] CyberKnife stereotactic body radiation therapy for palliation and local control in patients with advanced pancreatic cancer: A retrospective review
    Shirazi, R.
    Goldfarb, P. M.
    Fuller, D. B.
    Sanati, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [50] Computed tomography-based radiomic to predict resectability in locally advanced pancreatic cancer treated with chemotherapy and radiotherapy
    Rossi, Gabriella
    Altabella, Luisa
    Simoni, Nicola
    Benetti, Giulio
    Rossi, Roberto
    Venezia, Martina
    Paiella, Salvatore
    Malleo, Giuseppe
    Salvia, Roberto
    Guariglia, Stefania
    Bassi, Claudio
    Cavedon, Carlo
    Mazzarotto, Renzo
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 14 (03) : 703 - 715